Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment

التفاصيل البيبلوغرافية
العنوان: Relationship Between Bone Mineral Density T‐Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
المؤلفون: Rachel B. Wagman, A. Wang, Jean-Yves Reginster, L. H. de Gregόrio, Celia Jow Fang Lin, Edward Czerwiński, Felicia Cosman, Serge Ferrari, J. Malouf-Sierra, E. M. Lewiecki, Jacques P. Brown, Cesar Libanati
المصدر: Journal of Bone and Mineral Research
Dipòsit Digital de Documents de la UAB
Universitat Autònoma de Barcelona
Journal of Bone and Mineral Research, Vol. 34, No 6 (2019) pp. 1033-1040
JOURNAL OF BONE AND MINERAL RESEARCH
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
بيانات النشر: John Wiley and Sons Inc., 2019.
سنة النشر: 2019
مصطلحات موضوعية: 0301 basic medicine, Fracture risk, medicine.medical_specialty, Endocrinology, Diabetes and Metabolism, Osteoporosis, 030209 endocrinology & metabolism, Standard score, OSTEOPOROSIS, 03 medical and health sciences, Fractures, Bone, 0302 clinical medicine, Bone Density, Risk Factors, Internal medicine, Medicine, Humans, Orthopedics and Sports Medicine, Femoral neck, Aged, ddc:616, Bone mineral, DXA, Aged, 80 and over, Fracture riks assessment, Hip, FRACTURE RISK ASSESSMENT, Antiresoptives, business.industry, Incidence (epidemiology), Fracture risk assessment, ANTIRESORPTIVES, Treat to target, Original Articles, Denosumab therapy, medicine.disease, Antiresorptives, TREAT TO TARGET, 030104 developmental biology, Denosumab, medicine.anatomical_structure, Original Article, Female, business, medicine.drug
الوصف: Although treat-to-target strategies are being discussed in osteoporosis, there is little evidence of what the target should be to reduce fracture risk maximally. We investigated the relationship between total hip BMD T -score and the incidence of nonvertebral fracture in women who received up to 10 years of continued denosumab therapy in the FREEDOM (3 years) study and its long-term Extension (up to 7 years) study. We report the percentages of women who achieved a range of T -scores at the total hip or femoral neck over 10 years of denosumab treatment (1343 women completed 10 years of treatment). The incidence of nonvertebral fractures was lower with higher total hip T -score. This relationship plateaued at a T -score between -2.0 and -1.5 and was independent of age and prevalent vertebral fractures, similar to observations in treatment-naïve subjects. Reaching a specific T -score during denosumab treatment was dependent on the baseline T -score, with higher T -scores at baseline more likely to result in higher T -scores at each time point during the study. Our findings highlight the importance of follow-up BMD measurements in patients receiving denosumab therapy because BMD remains a robust indicator of fracture risk. These data support the notion of a specific T -score threshold as a practical target for therapy in osteoporosis. © 2019 The Authors Journal of Bone and Mineral Research published by Wiley Periodicals, Inc. on behalf of American Society for Bone and Mineral Research (ASBMR)
وصف الملف: application/pdf
اللغة: English
تدمد: 1523-4681
0884-0431
URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96d0ce6569836c3d3b7d25d208c71943
http://europepmc.org/articles/PMC6852155
حقوق: OPEN
رقم الأكسشن: edsair.doi.dedup.....96d0ce6569836c3d3b7d25d208c71943
قاعدة البيانات: OpenAIRE